Anavex Life Sciences has reported promising results from its investigational therapy, Anavex 2-73, in
reducing symptoms of Parkinson’s disease dementia. This breakthrough was
highlighted in a recent extension study of their Phase 2 trial, showcasing the
potential effectiveness of this innovative treatment.
The extension study involved 20 participants who had previously completed the Phase 2 ANAVEX
2-73-PDD-001 trial. Over the course of one year, these patients received daily
doses of Anavex 2-73. During the interim period between the end of the initial
trial and the beginning of the extension study, participants experienced a
noticeable worsening of symptoms. This decline underscored the need for
continuous treatment to manage the disease effectively.
Anavex Life Sciences’ findings revealed that patients undergoing long-term treatment
with Anavex 2-73 showed significant improvements in both motor and non-motor
symptoms. Specifically, the therapy helped maintain cognitive functions and
reduced the severity of motor impairments. These findings were assessed using
the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale
(MDS-UPDRS), which is a critical measure in evaluating the progression of Parkinson’s disease.
Shortly after resuming Anavex 2-73, participants exhibited a reversal of symptom progression,
bringing their condition back to levels observed at the end of the original
Phase 2 trial. This result indicates that Anavex 2-73 not only halts but may
also reverse the damage caused by Parkinson’s disease dementia during periods without treatment.
The experimental therapy was well tolerated among patients, aligning with the safety profile
observed in previous studies. Encouraged by these outcomes, Anavex is planning a Phase 3
clinical trial to further test the efficacy and safety of Anavex 2-73.
The scientific community eagerly awaits the results of this upcoming trial, hopeful that
Anavex 2-73 will provide a much-needed solution for those suffering from
Parkinson’s disease dementia. Read this article for additional information.
More about Anavex Life Sciences on https://www.clinicaltrialsarena.com/news/anavex-data-trial-alzheimers/